Trial of Five Versus Six Fractions Per Week for Head and Neck Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
International Atomic Energy Agency
ClinicalTrials.gov Identifier:
NCT00120211
First received: July 8, 2005
Last updated: October 12, 2011
Last verified: October 2011
  Purpose

This trial compares the use of 6 fractions versus the standard 5 fractions of radiotherapy used in the treatment of head and neck cancer.


Condition Intervention Phase
Head and Neck Cancer
Radiation: Accelerated Radiotherapy Fractionation
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase III Trial of Five Versus Six Fractions Per Week for Head and Neck Cancer

Resource links provided by NLM:


Further study details as provided by International Atomic Energy Agency:

Primary Outcome Measures:
  • Three Years Loco-regional Control [ Time Frame: 3 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Disease-specific Survival [ Time Frame: 8 years ] [ Designated as safety issue: No ]
  • Overall Survival [ Time Frame: 8 years ] [ Designated as safety issue: No ]
  • Acute Adverse Effects [ Designated as safety issue: Yes ]
  • Late Adverse Effects [ Time Frame: 8 years ] [ Designated as safety issue: Yes ]

Enrollment: 855
Study Start Date: September 1998
Study Completion Date: May 2006
Primary Completion Date: May 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Radiotherapy: 6 Fractions Radiation: Accelerated Radiotherapy Fractionation
Radiation Therapy 6 fractions per week
Active Comparator: Radiotherapy: 5 fractions Radiation: Accelerated Radiotherapy Fractionation
Radiotherapy 5 fractions per week

Detailed Description:

The purpose of this trial is to study the clinical effects of increasing the weekly fraction number for locally advanced head and neck cancers by a multi-institutional prospective randomised trial. The primary endpoint is to clarify whether a six fraction per week protocol has a greater effect on the survival, as compared to the conventional five fraction per week protocol.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Head and Neck Cancer

Exclusion Criteria:

  • Unable to give an informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00120211

Sponsors and Collaborators
International Atomic Energy Agency
Investigators
Study Director: Eduardo Rosenblatt, M.D. International Atomic Energy Agency (IAEA)
  More Information

Additional Information:
No publications provided by International Atomic Energy Agency

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: International Atomic Energy Agency
ClinicalTrials.gov Identifier: NCT00120211     History of Changes
Other Study ID Numbers: E33018
Study First Received: July 8, 2005
Last Updated: October 12, 2011
Health Authority: United Nations: International Atomic Energy Agency

Additional relevant MeSH terms:
Head and Neck Neoplasms
Neoplasms by Site
Neoplasms

ClinicalTrials.gov processed this record on August 28, 2014